French biopharma firm Adocia H1 revenue drops on weaker feasibility study income

Adocia SA

24/09/2026 17:10

Overview
France biopharma firm's H1 2026 revenue fell sharply due to lower feasibility study income
Net loss for H1 2026 narrowed slightly as operating expenses decreased
Company flagged material uncertainty on going concern, cash runway seen through early Q2 2027

Outlook
Company says cash runway secured until beginning of Q2 2027, assuming no new partnership revenue
Company discloses material uncertainty regarding going concern in half-year report
Company is seeking additional financing and new strategic partnerships while reducing costs

Result Drivers
FEASIBILITY STUDY INCOME - H1 2026 revenue was mainly from a feasibility study on a novel peptide combination using BioChaperone, with lower income than prior year studies
OPERATING EXPENSES REDUCTION - Lower operating expenses due to reduced share-based payment expense, foreign exchange impact, and decreased personnel costs
FINANCIAL EXPENSES INCREASE - Higher financial expenses from non-cash IFRS charge for warrants linked to shareholder loan, partly offset by investment income

Company press release: ID:nBw1Tp20xa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Loss
 
EUR 8.64 mln
 
H1 Adjusted Operating Expenses
 
-EUR 9.02 mln
 
H1 Current Operating Income
 
-EUR 7.95 mln
 
H1 Operating Income
 
-EUR 7.95 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Adocia SA is €12.00, about 239.6% above its September 23 closing price of €3.53

Reuters Recommended Reads
Sept 21 - France's Abivax H1 net loss widens on higher expenses driven by clinical programs
Sept 23 - France's ABIONYX Pharma H1 net loss widens as financial expenses rise
Sept 24 - France's Transgene H1 operating income falls on lower tax credit

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)